Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 12/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 0.43 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2564105 | 0.84 | ACACB (0.52) | PRMT5WDR77ACACBPDE4BHRH3 | |
| SCHEMBL2561454 | 0.81 | HRH3 (0.46) | PRMT5WDR77ACACBCYP2D6HRH3 | |
| SCHEMBL2560796 | 0.79 | DRD2 (0.50) | PRMT5WDR77ACACBCYP2D6HRH3 | |
| SCHEMBL2566679 | 0.79 | ACACB (0.46) | PRMT5WDR77ACACBCYP2D6HRH3 | |
| SCHEMBL2561968 | 0.79 | HRH3 (0.61) | PRMT5WDR77ACACBCYP2D6HRH3 | |
| Oxalic Acid SCHEMBL3550835 | 0.74 | HRH3 (0.56) | PRMT5WDR77ACACBCYP2D6HRH3 | |
| SCHEMBL21509746 | 0.70 | ALDH1A1 (0.64) | KDM4EALDH1A1ALOX15TSHRCASP1 | |
| SCHEMBL6973623 | 0.69 | ALDH1A1 (0.63) | KDM4EALDH1A1ALOX15TSHRCASP1 | |
| SCHEMBL28992968 | 0.67 | KDM4E (0.57) | KDM4EALDH1A1ALOX15TSHRCASP1 | |
| SCHEMBL10679512 | 0.67 | KDM4E (0.63) | KDM4EALDH1A1ALOX15TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960387-B1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | SANOFI SA (FR) | 2011-11-02 | — | — | EP | claimed |
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | claimed |
| EP-1960387-A1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | sanofi-aventis (FR) | 2008-08-27 | — | — | EP | claimed |
| WO-2007060027-A1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | SANOFI AVENTIS (FR) | 2007-05-31 | — | — | WO | claimed |
| EP-1790646-A1 | Isoquinoline und benzo[h]isoquinoline derivatives, their preparation and their therapeutical application as antagonists of histamine H3 receptor . | Sanofi-Aventis (FR) | 2007-05-30 | — | — | EP | claimed |
| EP-1960387-B1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | SANOFI SA (FR) | 2011-11-02 | — | — | EP | disclosed |
| US-7678807-B2 | Isoquinoline and benzo[H] isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of the histamine H3 receptor | SANOFI-AVENTIS (FR) | 2010-03-16 | — | — | US | disclosed |
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| EP-1960387-A1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | sanofi-aventis (FR) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060027-A1 | ISOQUINOLINE ET BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | SANOFI AVENTIS (FR) | 2007-05-31 | — | — | WO | disclosed |
| EP-1790646-A1 | Isoquinoline und benzo[h]isoquinoline derivatives, their preparation and their therapeutical application as antagonists of histamine H3 receptor . | Sanofi-Aventis (FR) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH1, HRH2 | KDM4E 1797/4885ALDH1A1 831/4885ALOX15 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.